Top Story
Cease-production order against Cody Labs stands
Wyoming-based drugmaker Cody Labs is facing the shutdown of a portion of its business that contributes one-third of its sales. A U.S. district judge recently denied the company's request to halt FDA enforcement of a cease-production order that the regulator issued more than a year ago for unapproved morphine sulfate in 20-milligram-per-milliliter dosages. Report
Latest News
Also Noted
> Big 3 drug distributor Amerisource cites sales of generics as a driver in its higher-than-expected quarterly profit growth. Article
> The FDA has approved Orthovita's facility in Malvern, PA, for collagen processing and the manufacture of collagen-based products. Article
> Novavax has been issued U.S. Patent No. 7,763,450, "Functional Influenza Virus-Like Particles (VLPS)," for the manufacturing process that uses influenza gene sequences for production of vaccines to protect against current and future seasonal and pandemic flu strains. Release
> Meridian Life Science is boosting investment in facilities, equipment and infrastructure to provide R&D support for contract manufacturing and custom biologics development. Release
Read more >>Special Report
Top 10 Pharma Cargo Thefts by Value, 2009/2010
Big pharma means big money, especially for thieves. In a much publicized and spectacular heist, burglars made off with $75 million worth of drugs from an Eli Lily warehouse in Connecticut last March. That's one high-value hit. But it's just one incident in a growing crime wave targeting pharmaceuticals. Report
Feature
Expert tips for REMS success
Start earlier than you plan to, challenge your own thinking, dig hard, and reach out to prescribers and patients. These tactics may be the keys to developing a successful risk evaluation and mitigation strategy (REMS), and to developing it as painlessly as possible. Report
From The Network
Press Releases
- GSK EXERCISES OPTION ON ANACOR'S NOVEL ANTIBIOTIC FOR THE TREATMENT OF GRAM-NEGATIVE INFECTIONS
- Formatech to Donate Services to Formulate and Fill Femta Pharmaceuticals’ FM101 Monoclonal Antibody under Its “Fillanthrop
- Inhibitex to Host Conference Call to Report Second Quarter Financial Results on August 10, 2010
- Amgen’s Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38
- Response Genetics, Inc. to Announce Second Quarter 2010 Financial Results
- The Multiple Myeloma Research Foundation (MMRF) Names Walter Capone Chief Operating Officer
